Company intelligence / Profile preview

UCL Business

London, England, United Kingdomuclb.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

UCL Business enables the translation of world-class academic research into real-world therapies and products. It has successfully commercialized multiple advanced therapies including the first approved gene therapy for haemophilia A ("Roctavian"), novel gene therapies for inherited blindness, breakthrough treatments for motor neurone disease now in clinical trials, and an FDA-approved CAR-T cell therapy for aggressive leukemia.

Therapeutic areas: OncologyOphthalmologyNeurologyHematology
Modalities: Gene therapyCAR-T cell therapySmall moleculeMonoclonal antibodyAntibody-drug conjugate (ADC)Cell therapyBiologic
Industry: Investors

Partnerships

BioMarin PharmaceuticalsMeiraGTxTrace NeuroscienceAutolusGlaxoSmithKline/GSK

Beyond the preview

Go deeper on UCL Business.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UCL Business.

Explore the full profile